Q-Med AB Has Entered Into A Development And Commercialisation Agreement With Medy-Tox Inc. Regarding Botulinum Toxin Products

STOCKHOLM, Sweden--(BUSINESS WIRE)--Q-Med AB (STO:QMED) and Medy-Tox Inc., a South Korean biopharmaceutical company, have today entered into an agreement regarding collaboration with regard to botulinum toxin based biopharmaceuticals.